

MAGNIFY: Phase IIIb interim analysis of induction R² followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma.

Presented Monday, June 3, 2019

Authors:

David Jacob Andorsky, Morton Coleman, Abdulraheem Yacoub, Jason M. Melear, Suzanne R. Fanning, Kathryn Kolibaba, Frederick Lansigan, Chris Reynolds, Kenneth A. Foon, Jiahui Li, Mary Llorente, Mathias J. Rummel, Jeff Porter Sharman; Rocky Mountain Cancer Centers, US Oncology Research, Boulder, CO; Clinical Research Alliance Weill Cornell Medicine, New York, NY; The University of Kansas Cancer Center, Westwood, KS; Texas Oncology - Austin, US Oncology Research, Austin, TX; Greenville Health System, US Oncology Research, Greenville, SC; Compass Oncology, US Oncology Research, Vancouver, WA; Dartmouth-Hitchcock Medical Center, Lebanon, NH; IHA Hematology Oncology Consultants—Ann Arbor, Ypsilanti, MI; Celgene Corporation, Summit, NJ; Department of Haematology and Oncology, Justus-Liebig Universität, Giessen, Germany; Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR

[View Less](#)

Abstract Disclosures

Background:

Standard treatment is lacking for patients with relapsed indolent NHL (iNHL). PI3K inhibitors reported a median PFS of < 1 y in R/R iNHL. The immunomodulatory agent lenalidomide shows enhanced activity with rituximab (ie, R²), which recently reported a 39.4-mo median PFS in R/R iNHL patients (AUGMENT; Leonard. ASH 2018:445).

Methods:

MAGNIFY is a multicenter, non-registrational phase IIIb trial in patients with R/R FL grade 1-3a and MZL designed to determine the optimal duration of lenalidomide. Lenalidomide 20 mg/d, d1-21/28 + rituximab 375 mg/m²/wk c1 and q8wk c3+ (R²) are given for 12c followed by 1:1 randomization in patients with stable disease or better to continued R² vs rituximab maintenance. These analyses evaluate the primary endpoint of ORR by 1999 IWG criteria for induction R² in efficacy-evaluable patients receiving ≥ 1 treatment with baseline/post-baseline assessments.

Results:

At a median 16.7 mo follow-up, 370 patients (80% FL grade 1-3a; 20% MZL) were enrolled with a median age of 66 y, 83% stage III/IV disease, and a median of 2 prior therapies (95% prior rituximab-containing). Efficacy-evaluable patients showed a 73% ORR and 45% CR (Table). Median TTR was 2.7 mo, median DOR was 36.8 mo, and median PFS was 36.0 mo. 142 of 370 patients have been randomized and entered maintenance. The most common all-grade AEs were 48% fatigue, 40% neutropenia, 35% diarrhea, 30% nausea, and 29% constipation. Grade 3/4 AE neutropenia was 34%; all other grade 3/4 AEs were < 6%.

Conclusions:

R² therapy is active with a tolerable safety profile in patients with R/R FL and MZL, and in patients refractory to rituximab. Clinical trial information: [NCT01996865](https://clinicaltrials.gov/ct2/show/study/NCT01996865)

Efficacy for Induction R² in R/R iNHL.

	ORR, %	CR, %	Median TTR, mo (range)	Median DOR, mo (95% CI)*	Median PFS, mo (95% CI)*
Overall	73	45	2.7 (1.6-12.0)	36.8 (35.8-NR)	36.0 (26.0-46.0) <small>Print</small>
By histology					
FL gr 1-3a	74	46	2.8 (1.6-12.0)	NR (27.7-NR)	30.2 (23.0-NR)
MZL	65	38	2.7 (1.9-11.1)	35.8 (NR-NR)	38.4 (26.5-38.4)
R-refractory status					
Yes	63	40	2.8 (1.6-12.0)	35.8 (19.2-NR)	18.1 (15.5-26.5)
No	78	47	2.7 (1.6-11.6)	NR (36.8-NR)	NR (36.0-NR)

*If patients were already in maintenance at data cutoff, then response assessments also contributed to DOR and PFS.